Researchers who examined lung samples from 100 people undergoing bronchoscopy found microplastic particles in 70 percent of them and found them more often and in greater quantity among the 50 patients later diagnosed with lung cancer than among the 50 who were not.
Detectable microplastics appeared in airway wash samples from 66 percent of patients with cancer compared with 46 percent of those without. Across all samples, investigators counted 232 particles. When each patient's airway wash and tissue results were analyzed together, patients with cancer were both more likely to have detectable microplastics and had a higher total burden.
The study cannot say which came first. That is not a caveat added at the end by a cautious reporter. It is a limitation the lead investigator raised himself.
The Direction of Cause Is Genuinely Open
Dr Ilias Dimeas of University College Dublin School of Medicine and the University of Thessaly, who led and presented the work, has said publicly that diseased lungs may simply retain particles differently than healthy ones rather than the particles contributing to cancer. A tumor changes the architecture and clearance mechanics of the tissue around it, and a lung that clears particles less efficiently will accumulate more of them.
Nothing in a study measuring both things at once can distinguish that explanation from the reverse. Patients were enrolled at the University Hospital of Larissa in Greece while undergoing bronchoscopy to investigate lung symptoms, and diagnosis came afterward. Each provided a bronchoalveolar lavage sample, in which saline is used to wash out a section of lung, and half also provided a small tissue sample.
"Microplastics have become an unavoidable part of our environment," Dimeas said, according to the society release describing the work, adding that little is known about what happens once they enter the body.
An Unexpected Result About Where Particles Sit
One finding was not about cancer at all and may prove more durable. When researchers compared the two sample types from the same person, patients with more microplastic in the airway wash tended to have less in the corresponding tissue sample, and the reverse held as well.
Because lung wash samples collect particles from the airspaces while tissue samples capture particles embedded in the lung itself, that pattern suggests microplastics are not distributed evenly through the lung and that different regions retain them differently. It also carries a methodological warning for the whole field. Studies that sample only one compartment may be measuring something quite narrow while reporting it as lung burden.
Polypropylene and polyethylene, both used heavily in packaging, textiles, household materials and consumer goods, were the most common polymer types identified, according to the announcement from University College Dublin. The same announcement records that the study received no external funding and was carried out with resources from the university's respiratory medicine department.
The Evidence Standard This Has Not Met
The study included 100 people at a single hospital and has been presented as a conference abstract without peer review. It measured association at one point in time, in patients already symptomatic enough to need a bronchoscopy, which is not a general population. The researchers have also said they gathered additional data after submitting the abstract, so published figures may shift.
The comparison group is a specific one worth naming. The 50 patients without a cancer diagnosis were also undergoing bronchoscopy for lung symptoms, so this is not a comparison against healthy lungs. That design choice reduces some confounding and introduces other questions about who the findings generalize to.
Smoking is the most obvious unresolved variable. It is the dominant cause of lung cancer, it alters particle clearance, and the presentation materials available do not describe how smoking history was accounted for between groups. Until the full analysis is published, that gap is significant. Occupational exposure is a second open question, since people who work in textile manufacturing, plastics processing or construction breathe measurably more airborne particles than the general population.
Professor Barbara Hoffmann, chair of the society's Advocacy Council at the University of Düsseldorf, who was not involved in the research, said more work is needed to understand any role microplastics play in lung diseases including cancer. "These tiny pieces of plastic are infiltrating many parts of the body," she said, while noting that smoking remains by far the biggest cause of lung cancer and that air pollution is now also established as a cause.
Practical Meaning for Households Right Now
There is no medical test for microplastics in the lungs, no treatment to remove them, and no clinical guidance that has changed. Anyone offering a test or a detox for microplastic exposure is selling something unsupported by evidence.
The exposures involved are also not primarily about individual consumer choices. If the particles are arriving through the air people breathe, as the researchers propose, then indoor and outdoor air are the pathway, and swapping water bottles does not address it. Measures that plausibly reduce airborne particle exposure indoors, such as HEPA filtration and adequate ventilation, are the same measures already recommended for other pollutants and are supported on those grounds regardless. The society's environment and health program makes the same argument at the policy level.
The established priorities for lung cancer risk have not moved. Not smoking, quitting for those who do smoke, testing homes for radon, and following screening guidance remain the interventions with strong evidence behind them. The U.S. Preventive Services Task Force recommends annual low dose CT screening for adults aged 50 to 80 with a 20 pack year smoking history who currently smoke or quit within the past 15 years, and lung cancer remains among the leading causes of cancer death in the United States.
Dimeas and colleagues are continuing laboratory work to characterize how the plastic types they identified may interact with lung cells, and are separately analyzing samples from patients with chronic lung disease to assess whether microplastics contribute to scarring and disease progression. Those results have not been reported.
Key Questions Answered
What did the study find? Among 100 patients undergoing bronchoscopy, 70 percent had detectable microplastics. Patients later diagnosed with lung cancer had them more often, 66 percent versus 46 percent in airway samples, and in greater total quantity.
Does this show microplastics cause lung cancer? No. The lead investigator has said diseased lungs may simply retain particles differently. The study cannot establish direction of cause.
What kinds of plastic were found? Polypropylene and polyethylene were the most common types identified, both widely used in packaging, textiles, and consumer products.
Who were the comparison patients? Fifty patients at the same hospital who were also undergoing bronchoscopy for lung symptoms but were not diagnosed with cancer. They were not healthy volunteers.
Is there a test for microplastics in the lungs? No. There is no clinical test, no treatment to remove them, and no product that credibly does either.
What was the unexpected finding about distribution? Particle counts in airway wash samples and tissue samples did not track together and tended to run in opposite directions, suggesting uneven distribution through the lung.
What still reduces lung cancer risk? Not smoking, quitting, radon testing at home, and low dose CT screening for adults aged 50 to 80 with a 20 pack year history who smoke or quit within the past 15 years.
